Affimed’s Bispecific Innate Cell Engagers: Activating CD16A for Tumor Cell Killing

Time: 10:15 am


• Deep dive into Affimed’s ROCK® platform allows development of high affinity Innate Cell Engagers that activate all variants of CD16A
• Learn how innate cell engagers can be designed to target a multitude of tumor antigens
• Examine how clinical data have shown early signs of efficacy and a promising safety profile for Affimed’s lead candidate